The Oncology Podcast

Send us Fan Mail

In this special ASCO 2026 edition of The Oncology Journal Club, Craig Underhill, Chris Jackson and Kate Clarke unpack some of the meeting’s most talked-about studies and discuss what they could mean for clinical practice.

From the PROTEUS trial in high-risk prostate cancer and promising advances in RET fusion-positive lung cancer, to a rare sarcoma study demonstrating the potential of CDK4 inhibition, the team explores the data behind the headlines and highlights the challenges of translating trial results into real-world care.

The episode also dives into what many are calling the breakthrough study of the meeting – the RESOLUTE-302 trial of daraxonrasib in previously treated pancreatic cancer. With a striking overall survival benefit in a disease that has seen few meaningful advances, the results sparked excitement throughout the oncology community.

Along the way, the panel reflects on the atmosphere at ASCO, emerging trends in precision oncology, and how new therapeutic approaches such as KRAS inhibitors, bispecific antibodies and antibody-drug conjugates are reshaping the future of cancer treatment.

The Oncology Journal Club Podcast is hosted by Professor Craig Underhill, Dr Kate Clarke and Professor Chris Jackson, and proudly produced by The Oncology Network

Visit oncologynetwork.com.au for Show Notes, to send us Voice Notes and more information. And to download your bingo card if you'd like to play along with the team!

Send us Fan Mail

In this episode of The Oncology Journal Club, the team cover one of the most talked-about pancreatic cancer papers of the year, unpacking the promising early results for daraxonrasib in previously treated RAS-mutated pancreatic cancer and the science behind new RAS(ON) therapeutics. 

The team also discuss a fascinating phase II study of single-cycle neoadjuvant pembrolizumab in MMR-deficient colon cancer, new recommendations from the Prostate Cancer Working Group 4 and why the terminology we use in prostate cancer matters.

Along the way, there’s discussion of Bob Marley’s acral melanoma, multidisciplinary lung cancer meetings, androgen receptor-positive TNBC, HER2-mutant lung cancer and whether oxybutynin could help men experiencing androgen deprivation-related hot flushes.

The Oncology Journal Club Podcast is hosted by Professor Craig Underhill, Dr Kate Clarke and Professor Chris Jackson, and proudly produced by The Oncology Network

Visit oncologynetwork.com.au for Show Notes, to send us Voice Notes and more information. 

Send us Fan Mail

Proudly Produced by The Oncology Network

Professor Craig Underhill and Rachael Babin break down the key oncology changes from the May 2026 PBS update.

This month we run through 3 fresh PBS listings that affect Australian oncology and haematology practice, from fruquintinib, a late-line colorectal cancer treatment, through to new haematology options.  

Follow The PBS Update for regular discussions of PBS listings and oncology policy changes affecting Australian healthcare professionals.

Visit the Show Notes for links to the updates discussed in this episode and to send us audio feedback or questions for future episodes.

Send us Fan Mail

In this episode of The Oncology Journal Club, the team weigh promising trial signals against the level of evidence needed to change clinical practice. From perioperative cholangiocarcinoma to molecular matching and chrono-oncology, the focus stays on a key question: what meaningfully improves outcomes for patients?

What’s covered

•  NeoGOLP trial in high-risk resectable iCCA: improved event-free survival; overall survival still immature 
•  MoST programme: molecular matching and survival associations when therapies align with biomarkers 
•  Genomic therapy matching in clinical decision-making 
•  Chrono-oncology: does treatment timing influence outcomes? 
•  CHOPIN phase II uveal melanoma trial: combination therapy signals and feasibility 
•  ASCO living guideline updates across lung, gastro-oesophageal and thyroid cancers 

The Oncology Journal Club Podcast hosted by Professor Craig Underhill, Dr Kate Clarke and Professor Chris Jackson, and proudly produced by The Oncology Network

Visit oncologynetwork.com.au for Show Notes, to send us Voice Notes and more information. 

Send us Fan Mail

Proudly Produced by The Oncology Network

Professor Craig Underhill and Rachael Babin break down the key oncology changes from the April 2026 PBS update.

This month we run through six fresh PBS listings and policy changes that affect Australian oncology and haematology practice, from ROS1-positive non small cell lung cancer to perioperative immunotherapy and late-line blood cancer options. 

We focus on who benefits, what the key trial signals are and what clinicians need to monitor so access translates into safe, real-world outcomes. 

• Repotrectinib listed for ROS1-positive NSCLC, including activity after prior TKIs and in resistant mutations, plus monitoring for dizziness and pneumonitis 
• Durvalumab listed for muscle-invasive bladder cancer using the Niagara perioperative regimen, balancing survival gains with immune-related toxicity 
• Three new pembrolizumab listings across cervical cancer, adjuvant renal cell carcinoma and perioperative head and neck cancer, with discussion of endpoints and eligibility 
• Haematology additions including a BCMA bispecific for relapsed myeloma, an oral kinase inhibitor for higher-risk myelofibrosis and mogamulizumab for cutaneous T-cell lymphoma 
• PBS price cuts via generics and biosimilars, plus expanded supervised prescribing for some medicines by nurse practitioners

Follow The PBS Update for regular discussions of PBS listings and oncology policy changes affecting Australian healthcare professionals.

Visit the Show Notes for links to the updates discussed in this episode and to send us audio feedback or questions for future episodes.

Send us Fan Mail

Australia’s PBS has introduced it’s first pan-tumour reimbursement listing for the immunotherapy combination nivolumab plus ipilimumab. In this inaugural episode of PBS Update, Professor Craig Underhill and Rachael Babin break down the key oncology changes from the March 2026 PBS update, including new listings for toripalimab and cabozantinib.

Follow PBS Update for regular discussions on PBS listings and oncology policy changes affecting Australian healthcare professionals.

Visit the Show Notes for links to the PBS updates discussed in this episode and to send us audio feedback or questions for future episodes.

Send us Fan Mail

The Oncology Journal Club Podcast hosted by Professor Craig Underhill, Dr Kate Clarke and Professor Chris Jackson | Proudly Produced by The Oncology Network

Visit oncologynetwork.com.au for Show Notes, to send us Voice Notes and more information. 

We explore practical wins and bold ideas across supportive care, colorectal cancer prevention, immunotherapy timing, digital triage and equity. From halving hot flushes with an NK1/NK3 blocker to biomarker-guided aspirin in colon cancer, we weigh value, risk and what truly improves lives.

• Elinzanetant cutting severe hot flushes and improving treatment adherence
• Current non-hormonal options and gaps in symptom control
• Biomarker-selected aspirin reducing recurrences in colorectal cancer
• Limits of DFS, toxicity trade-offs and subgroup signals
• Rising early-onset colorectal cancer and system planning needs
• Possible environmental and microbiome drivers under study
• ASCO geriatric assessment guidance and G8 screening in clinics
• PD-1 with short-course radiotherapy boosting rectal pCR rates
• Large language models for safe, efficient symptom triage
• Rare cancers report on access, cost, and rural inequities
• Telehealth standards to link expertise closer to home
• Healthy workplace culture to retain a resilient oncology workforce

Join the Oncology Network, registration is free, and leave us a voice note on the OJC page at oncologynetwork.com.au. Physicians, don’t forget you can claim CME points for listening to the show!

Thanks for listening

Send us Fan Mail

Welcome back to The Oncology Journal Club podcast — our favourite episode of the year!

Hosted by Professor Craig Underhill, Dr Kate Clarke and Professor Christopher Jackson.

The team reflect on the achievements of 2025, highlighting key developments, initiatives and papers that have made — and will continue to make — a real impact on clinical practice. As CJ says, it’s a privilege to work in what is the “single most innovative and thoughtful field in all of medicine” — and we are indeed lucky to have our brains tickled every month by this wonderful podcast.

And of course, it wouldn’t be OJC without some laughs and a few naughty jokes — and this year, we even have the inaugural OJC Christmas haiku!

Thank you for listening. We hope you enjoy the final episode of The Oncology Journal Club for 2025.

Visit oncologynetwork.com.au for Show Notes and more information. 

Proudly produced by the team at the Oncology Network

Send us Fan Mail

Welcome to The Oncology Journal Club Podcast Series 3
Hosted by Professor Craig Underhill, Dr Kate Clarke & Professor Christopher Jackson | Proudly produced by The Oncology Network

Welcome back to The Oncology Journal Club podcast, your essential dose of the latest oncology research, expert analysis and our trademark blend of healthy scepticism and bad jokes.

Hosted by Professor Craig Underhill, Dr Kate Clarke and Professor Christopher Jackson.

This week’s episode really does contain multitudes, with an incredibly eclectic mix of papers.

• Craig looks at the effectiveness of cancer control measures and optimising drug dosages.
• Kate talks us through interactions between solid neoplasms and the microbiome and shares a curious paper on extra virgin olive oil.
• CJ tackles a sobering paper on substandard anticancer medications and what lessons can be learnt from KEYNOTE-585 and Matterhorn in gastric cancer.

We’ve a great selection of Quick Bites and a heartfelt discussion about taboo thoughts and the challenges carers of people with brain cancer face.

To learn more about The Oncology Network, subscribe to our free weekly Newsletter and listen to other fantastic podcasts, visit our website: www.oncologynetwork.com.au. You'll also find the Show Notes on the website with links to papers, a transcript and bios of our hosts.

Send us Fan Mail

Welcome to The Oncology Journal Club Podcast Series 3
Hosted by Professor Craig Underhill, Dr Kate Clarke & Professor Christopher Jackson | Proudly produced by The Oncology Network

Kate Clarke takes over hosting duties!

Join our expert trio — Professor Craig Underhill, Dr Kate Clarke and Professor Christopher Jackson — for the usual OJC antics in Part 2 of our ESMO Special.

Craig talks us through the GU and lung highlights, while the team each share their top ‘practice-changing’ abstracts. Plus, CJ chats with Susie Stanway about the upcoming London Global Cancer Week.

Expect nuanced analysis, sharp insights and the occasional cheeky joke along the way.

To learn more about The Oncology Network, subscribe to our free weekly Newsletter and listen to other fantastic podcasts, visit our website: www.oncologynetwork.com.au. You'll also find the Show Notes on the website with links to the abstracts, bios of our hosts and a downloadable Bingo Card😂